共 834 条
[1]
Schmid P(2018)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer N Engl J Med 379 2108-2121
[2]
Adams S(2019)Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial Lancet 393 2051-2058
[3]
Rugo HS(1995)Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 Science 270 985-988
[4]
Palma DA(1995)Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 541-547
[5]
Olson R(2010)The PD-1 pathway in tolerance and autoimmunity Immunol Rev 236 219-242
[6]
Harrow S(2008)PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 677-704
[7]
Waterhouse P(2012)Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer Breast Cancer Res Treat 132 793-805
[8]
Penninger J(2015)Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab JAMA Oncol 1 448-454
[9]
Timms E(2018)Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Lancet Oncol 19 40-50
[10]
Wakeham A(2013)Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 J Clin Oncol 31 860-867